Rapid Micro Biosystems (NASDAQ:RPID) COO Sells $41,484.96 in Stock

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) COO John Addington Wilson sold 9,603 shares of Rapid Micro Biosystems stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $4.32, for a total value of $41,484.96. Following the sale, the chief operating officer directly owned 316,762 shares in the company, valued at $1,368,411.84. The trade was a 2.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Rapid Micro Biosystems Trading Down 17.3%

NASDAQ:RPID opened at $2.83 on Friday. Rapid Micro Biosystems, Inc. has a 1 year low of $1.86 and a 1 year high of $4.94. The stock has a market cap of $125.43 million, a price-to-earnings ratio of -2.64 and a beta of 1.38. The business has a fifty day moving average of $3.97 and a 200-day moving average of $3.54. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 4.23.

Rapid Micro Biosystems (NASDAQ:RPID) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). The business had revenue of $11.28 million for the quarter, compared to analyst estimates of $10.93 million. Rapid Micro Biosystems had a negative net margin of 140.30% and a negative return on equity of 86.01%. Equities analysts predict that Rapid Micro Biosystems, Inc. will post -1.1 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on RPID shares. Wall Street Zen lowered shares of Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Rapid Micro Biosystems has a consensus rating of “Hold” and a consensus target price of $8.00.

Key Rapid Micro Biosystems News

Here are the key news stories impacting Rapid Micro Biosystems this week:

• Positive Sentiment: Record revenue and raised 2026 outlook — RPID reported Q4 revenue of $11.3M and full‑year 2025 revenue of $33.6M (both record levels) and set 2026 revenue guidance of $37.0M–$41.0M with 30–38 expected system placements, signaling ongoing commercial traction. GlobeNewswire: Record Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Large customer follow‑on orders — The company announced multi‑system orders from Samsung Biologics and expanded deployments with Amgen, validating Growth Direct adoption among big pharma/CDMOs and supporting recurring system + consumables revenue upside. GlobeNewswire: Samsung Biologics Order
• Positive Sentiment: Analyst commentary supports secular growth thesis — Independent write‑ups highlight big‑pharma adoption as a key growth driver that could expand recurring revenue (service/consumables) over time. Seeking Alpha: Big‑Pharma Adoption Driving Growth
• Neutral Sentiment: Guidance near consensus but execution risk remains — 2026 revenue midpoint is close to street expectations (~$39M) and gross margin guidance (~20%) is modest; outcomes depend on hitting system placement targets and margin improvement. Yahoo Finance: Q4 2025 Earnings Preview
• Neutral Sentiment: Earnings‑call tone mixed — Management emphasized commercial progress but flagged margin and scaling pressures, producing a balanced (not unequivocally bullish) message. TipRanks: Earnings Call Summary
• Negative Sentiment: EPS miss and continued unprofitability — Q4 EPS of ($0.28) missed consensus ($0.23), and the company remains loss‑making with negative margins and ROE, a key near‑term concern for shareholders. MarketBeat: Q4 Earnings
• Negative Sentiment: Insider selling by multiple senior executives — Recent Form 4 filings show CEO, CFO and COO sales (CFO sold 7,480 shares at ~$4.32; CEO and COO also sold), which can amplify selling pressure or raise questions about insider conviction. InsiderTrades: Insider Selling

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in Rapid Micro Biosystems during the fourth quarter worth about $338,000. 683 Capital Management LLC acquired a new stake in Rapid Micro Biosystems in the 4th quarter valued at about $350,000. OMERS ADMINISTRATION Corp bought a new position in shares of Rapid Micro Biosystems during the 4th quarter valued at about $71,000. Fifth Lane Capital LP bought a new position in shares of Rapid Micro Biosystems during the 4th quarter valued at about $51,000. Finally, Barclays PLC acquired a new position in shares of Rapid Micro Biosystems in the 4th quarter worth approximately $72,000. Institutional investors own 52.60% of the company’s stock.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.